Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells

Cancer Biology and Therapy

Volumn 6, Issue 4, 2007, Pages 561-570

  Bonine Summers, Alyssa R ^a   Aakre, Mary E ^a   Brown, Kimberly A ^a   Arteaga, Carlos L ^a   Pietenpol, Jennifer A ^a   Moses, Harold L ^a   Cheng, Nikki ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

c Met; Cross talk; Epidermal growth factor receptor; Growth and breast cancer; Hepatocyte growth factor; Motility; Signaling; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ARTICLE; BIOLOGICAL ACTIVITY; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER CELL; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; HUMAN; HUMAN CELL; PROTEIN FUNCTION;

EID: 34548278840     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.4.3851     Document Type: Article

References (47)

1. Gherardi E, Stoker M. Hepatocyte growth factor-scatter factor: Mitogen, motogen, and met. Cancer Cells 1991; 3:227-32.
2. Jeffers M, Rao MS, Rulong S, Reddy JK, Subbarao V, Hudson E, Vande Woude GF, Resau JH. Hepatocyte growth factor/scatter factor-met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ 1996; 7:1805-13.
3. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991; 251:802-4.
4. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the met receptor. Embo J 1991; 10:2867-78.
5. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 1996; 119:591-600.
6. Weidner KM, Hartmann G, Naldini L, Comoglio PM, Sachs M, Fonatsch C, Rieder H, Birchmeier W. Molecular characteristics of hgf-sf and its role in cell motility and invasion. Exs 1993; 65:311-28.
7. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002; 13:41-59.
8. Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID, Rosen EM. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997; 79:749-60.
9. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, Shin S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54:1630-3.
10. Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K. Expression of the hepatocyte growth factor/c-met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001; 51:172-8.
11. Gallego MI, Bierie B, Hennighausen L. Targeted expression of hgf/sf in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene 2003; 22:8498-508.
12. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H. Cd44 is required for two consecutive steps in hgf/c-met signaling. Genes Dev 2002; 16:3074-86.
13. Bertotti A, Comoglio PM. Tyrosine kinase signal specificity: Lessons from the hgf receptor. Trends Biochem Sci 2003; 28:527-33.
14. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991; 47:87-98.
15. Wakeling AE. Inhibitors of growth factor signalling. Endocr Relat Cancer 2005; 12(Suppl 1):S183-7.
16. Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 2000; 259:293-9.
17. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. Faseb J 2003; 17:1640-7.
18. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-met signal pathways in transformed cells. J Biol Chem 2000; 275:8806-11.
19. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediate met receptor transactivation by g protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem 2004; 279:28970-8.
20. Scheving LA, Stevenson MC, Taylormoore JM, Traxler P, Russell WE. Integral role of the egf receptor in hgf-mediated hepatocyte proliferation. Biochem Biophys Res Commun 2002; 290:197-203.
21. Moriuchi A, Hirono S, Ido A, Ochiai T, Nakama T, Uto H, Hori T, Hayashi K, Tsubouchi H. Additive and inhibitory effects of simultaneous treatment with growth factors on DNA synthesis through mapk pathway and g1 cyclins in rat hepatocytes. Biochem Biophys Res Commun 2001; 280:368-73.
22. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of tgf-beta type ii receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of tgf-alpha-, msp- and hgf-mediated signaling networks. Oncogene 2005; 24:5053-68.
23. Day RM, Soon L, Breckenridge D, Bridges B, Patel BK, Wang LM, Corey SJ, Bottaro DP. Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. Oncogene 2002; 21:2201-11.
24. Day RM, Cioce V, Breckenridge D, Castagnino P, Bottaro DP. Differential signaling by alternative hgf isoforms through c-met: Activation of both map kinase and pi 3-kinase pathways is insufficient for mitogenesis. Oncogene 1999; 18:3399-406.
25. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. Zd1839 (iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-54.
26. Arteaga CL, Johnson DH. Tyrosine kinase inhibitors-zd1839 (iressa). Curr Opin Oncol 2001; 13:491-8.
27. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 2003; 284:31-53.
28. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. Zd1839 (iressa), a novel epidermal growth factor receptor (egfr) tyrosine kinase inhibitor, potently inhibits the growth of egfr-positive cancer cell lines with or without erbb2 overexpression. Int J Cancer 2001; 94:774-82.
29. Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor zd1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol 2003; 129:165-74.
30. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (egfr) signaling in cancer. Gene 2006; 366:2-16.
31. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M, Kruyt FA, Giaccone G. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006; 118:209-14.
32. Albanell J, Gascon P. Small molecules with egfr-tk inhibitor activity. Curr Drug Targets 2005; 6:259-74.
33. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor zd1839 (iressa). Mol Cancer Ther 2003; 2:345-51.
34. Yao Y, Jin L, Fuchs A, Joseph A, Hastings HM, Goldberg ID, Rosen EM. Scatter factor protein levels in human breast cancers: Clinicopathological and biological correlations. Am J Pathol 1996; 149:1707-17.
35. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the met proto-oncogene (hgf receptor). Oncogene 1994; 9:49-57.
36. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant egfr mutants. PLoS Med 2005; 2:e313.
37. Albitar L, Laidler LL, Abdallah R, Leslie KK. Regulation of signaling phosphoproteins by epidermal growth factor and iressa (zd1839) in human endometrial cancer cells that model type i and ii tumors. Mol Cancer Ther 2005; 4:1891-9.
38. Pierce JH, Ruggiero M, Fleming TP, Di Fiore PP, Greenberger JS, Varticovski L, Schlessinger J, Rovera G, Aaronson SA. Signal transduction through the egf receptor transfected in il-3-dependent hematopoietic cells. Science 1988; 239:628-31.
39. Ewald JA, Wilkinson JC, Guyer CA, Staros JV. Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32d cells. Exp Cell Res 2003; 282:121-31.
40. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J, Daub H. Cellular targets of gefitinib. Cancer Res 2005; 65:379-82.
41. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of her2/neu. Int J Cancer 2005; 113:678-82.
42. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of hgf-dependent invasive growth. Cell 2001; 107:643-54.
43. Grant S, Qiao L, Dent P. Roles of erbb family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002; 7:d376-89.
44. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn Jr WD, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. United states food and drug administration drug approval summary: Gefitinib (zd1839; iressa) tablets. Clin Cancer Res 2004; 10:1212-8.
45. Christensen JG, Burrows J, Salgia R. C-met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225:1-26.
46. Ma PC, Schaefer E, Christensen JG, Salgia RA. Selective small molecule c-met inhibitor, pha665752, cooperates with rapamycin. Clin Cancer Res 2005; 11:2312-9.
47. Namiki Y, Namiki T, Yoshida H, Date M, Yashiro M, Matsumoto K, Nakamura T, Yanagihara K, Tada N, Satoi J, Fujise K. Pre-clinical study of a "Tailor-made" Combination of nk4-expressing gene therapy and gefitinib (zd1839, iressatrade mark) for disseminated peritoneal scirrhous gastric cancer. Int J Cancer 2006; 118:1545-55.